Jade Biosciences entered into a worldwide, exclusive, sublicensable license with Paragon Therapeutics to develop and commercialize certain monospecific and multispecific antibodies against an undisclosed target. The deal includes up to $22.0 million in development and regulatory milestones, including $1.5 million already paid and $2.5 million due at first human dosing, plus up to approximately $20.1 million in sublicensing fees tied mainly to commercial milestones. Royalties range from low to mid-single digits for monospecific products and mid-single digits for multispecific products, with a 30% reduction where no valid patent exists. Paragon agreed not to start new monospecific campaigns against the target for at least five years, and the agreement is terminable on 60 days' notice.
Agreement details:
- Agreement type: Worldwide exclusive IP license for antibodies targeting an undisclosed target
- Counterparty: Paragon Therapeutics
- Signed / Effective: Jun 29 2026 / same
- Duration / Termination: Terminable on 60 days' notice; royalties to 12 years from first sale or patent expiry
- Reason: Advance pipeline with exclusive access to target-specific antibodies
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.